XML 71 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)
€ in Thousands
 1 Months Ended 6 Months Ended
Mar. 31, 2023
EUR (€)
target_option
Jun. 30, 2024
EUR (€)
preclinicalMolecule
Jun. 30, 2023
EUR (€)
Agreement with Sanofi, 2022      
Collaboration Liabilities, Roll Forward [Abstract]      
Payments for target options € 5,000    
Number of target options | target_option 2    
Payments for research work € 1,500    
Agreements with Sanofi for NK Cell engages      
Collaboration Liabilities, Roll Forward [Abstract]      
Payments for target options   € 5,000  
Number of target options | target_option 2    
Number of preclinical molecules | preclinicalMolecule   2  
Revenues from contract liabilities, period   3 years  
Payments for research work € 1,700 € 1,500  
Deferred revenue      
Deferred Revenue, Roll Forward [Abstract]      
Contract liabilities at beginning of period   10,481 € 14,481
Revenue for the six months period/Deductions   (3,396) (9,675)
Contract liabilities at end of period   6,915 11,024
Collaboration Liabilities, Roll Forward [Abstract]      
Contract liabilities at beginning of period   10,481 14,481
Contract liabilities at end of period   6,915 11,024
Deferred revenue | 2015 monalizumab agreement, with AstraZeneca      
Deferred Revenue, Roll Forward [Abstract]      
Contract liabilities at beginning of period   5,156 14,481
Revenue for the six months period/Deductions   (2,994) (9,503)
Transfer from / (to) collaboration liabilities   (172) (283)
Contract liabilities at end of period   1,990 4,695
Collaboration Liabilities, Roll Forward [Abstract]      
Contract liabilities at beginning of period   5,156 14,481
Contract liabilities at end of period   1,990 4,695
Deferred revenue | Agreement with Sanofi, 2022      
Deferred Revenue, Roll Forward [Abstract]      
Contract liabilities at beginning of period   5,327 0
Increase in deferred revenue/Additions   0 6,500
Revenue for the six months period/Deductions   (402) (172)
Contract liabilities at end of period   4,925 6,328
Collaboration Liabilities, Roll Forward [Abstract]      
Contract liabilities at beginning of period   5,327 0
Contract liabilities at end of period   4,925 6,328
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca      
Deferred Revenue, Roll Forward [Abstract]      
Contract liabilities at beginning of period   52,677 63,211
Contract liabilities at end of period   52,149 56,058
Collaboration Liabilities, Roll Forward [Abstract]      
Contract liabilities at beginning of period   52,677 63,211
Additions   1,891 283
Deductions   (2,419) (7,436)
Contract liabilities at end of period   € 52,149 € 56,058